Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist.
A common affliction of older men is bladder outlet obstruction secondary to benign prostatic hyperplasia for which the standard treatment is surgical prostatectomy. We report on six men with urinary retention from benign prostatic hyperplasia who were not medically able to undergo surgical prostatectomy but were successfully treated with the luteinizing hormone-releasing hormone (LH-RH) agonist, leuprolide acetate. This therapy is exemplified by the case of a sixty-six-year-old man with hemophilia B and urinary retention. The patient was treated with daily subcutaneous injections of 1 mg of leuprolide acetate, and prostatic size decreased from 132 g to 42 g, with initiation of spontaneous micturition while on treatment. For patients with symptomatic benign prostatic hyperplasia who are not candidates for surgery, treatment with an LH-RH agonist, such as leuprolide acetate, should be considered as a possible alternative.
Schlegel
P N
PN
James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Brendler
C B
CB
D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002836:Hemophilia B / Q000150:complications; D006801:Humans; D016729:Leuprolide; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000175:diagnosis; D014463:Ultrasonography; D014555:Urination Disorders / Q000188:drug therapy*
D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide